Advaxis, Inc. (NASDAQ:ADXS) had its Hold ➝ Neutral rating reiterated by HC Wainwright

Analyst Ratings For Advaxis, Inc. (NASDAQ:ADXS)

Story continues below

Today, HC Wainwright reiterated its Hold rating on Advaxis, Inc. (NASDAQ:ADXS).

There are 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings, no Buy Ratings on the stock.

The current consensus rating on Advaxis, Inc. (NASDAQ:ADXS) is Hold with a consensus target price of $3.00 per share, a potential 17.65% upside.

Some recent analyst ratings include

  • 6/12/2019-Advaxis, Inc. (NASDAQ:ADXS) had its Hold ➝ Neutral rating reiterated by HC Wainwright
  • 6/13/2018-Advaxis, Inc. (NASDAQ:ADXS) gets downgraded to Hold by Jefferies Financial Group with a price target of $2.00
  • On 4/10/2019 Roni Appel, Director, bought 3,000 with an average share price of $3.80 per share and the total transaction amounting to $11,400.00.
  • On 11/5/2018 Robert Petit, Insider, sold 3,963 with an average share price of $0.58 per share and the total transaction amounting to $2,298.54.
  • On 11/2/2018 Robert Petit, Insider, sold 8,491 with an average share price of $0.56 per share and the total transaction amounting to $4,754.96.
  • On 9/11/2018 Roni Appel, Director, bought 33,333 with an average share price of $1.20 per share and the total transaction amounting to $39,999.60.
  • On 4/2/2018 Robert Petit, Insider, sold 2,193 with an average share price of $1.62 per share and the total transaction amounting to $3,552.66.
  • On 2/2/2018 Anthony A Lombardo, CEO, sold 32 with an average share price of $2.93 per share and the total transaction amounting to $93.76.
  • On 1/3/2018 Sara Bonstein, CFO, sold 5,224 with an average share price of $3.18 per share and the total transaction amounting to $16,612.32.

About Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. Read More…

Recent Trading Activity for Advaxis, Inc. (NASDAQ:ADXS)
Shares of Advaxis, Inc. closed the previous trading session at 2.55 −0.020 0.78% with 2.53 shares trading hands.

An ad to help with our costs